[
    {
        "other_ids": [],
        "amendment_date": null,
        "keywords": null,
        "dcp_id": null,
        "interventional_model": "SEQUENTIAL_ASSIGNMENT",
        "lead_org": "Repare Therapeutics",
        "eligibility": {
            "unstructured": [
                {
                    "inclusion_indicator": true,
                    "display_order": 0,
                    "description": "Male or female and \u226518 years-of-age at the time of signature of the informed consent"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 1,
                    "description": "Confirmed advanced solid tumors resistant or refractory to standard treatment"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 2,
                    "description": "Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 3,
                    "description": "Measurable disease as per RECIST v1.1"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 4,
                    "description": "Next generation sequencing (NGS) report obtained in CLIA-certified or equivalent laboratory demonstrating eligible tumor biomarkers."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 5,
                    "description": "Submission of available tumor tissue or willingness to have a biopsy performed if safe and feasible"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 6,
                    "description": "Acceptable hematologic and organ function at screening"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 7,
                    "description": "Negative pregnancy test for women of childbearing potential at Screening and prior to first study drug."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 8,
                    "description": "Ability to swallow and retain oral medications."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 9,
                    "description": "Prior therapy with an ATR or DNA-dependent protein kinase (DNA-PK) inhibitor."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 10,
                    "description": "Chemotherapy, small molecule anticancer or biologic anticancer therapy given within 10 days or 5 half-lives (whichever is longer), prior to first dose of study drug."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 11,
                    "description": "Use of radiotherapy (except for palliative reasons) within 7 days prior to first dose of study drug."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 12,
                    "description": "History or current condition, therapy, or laboratory abnormality that might confound the study results, or interfere with the patient's participation for the full duration of the study treatment."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 13,
                    "description": "No other anticancer therapy is to be permitted while the patient is receiving study treatment."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 14,
                    "description": "Major surgery \u226428 days or minor surgical procedures \u22647 days prior to first study treatment dose."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 15,
                    "description": "Uncontrolled, symptomatic brain metastases."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 16,
                    "description": "Uncontrolled high blood pressure"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 17,
                    "description": "History of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) diagnosis"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 18,
                    "description": "Presence of other known active invasive cancers."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 19,
                    "description": "Pregnant or breastfeeding women."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 20,
                    "description": "Psychological, familial, sociological, or geographical conditions that do not permit compliance with the study protocol and/or follow-up procedures outlined in the protocol."
                }
            ],
            "structured": {
                "max_age": "999 Years",
                "max_age_number": 999.0,
                "min_age_unit": "Years",
                "max_age_unit": "Years",
                "max_age_in_years": 999.0,
                "gender": "BOTH",
                "accepts_healthy_volunteers": false,
                "min_age": "18 Years",
                "min_age_number": 18.0,
                "min_age_in_years": 18.0
            }
        },
        "completion_date_type_code": "ANTICIPATED",
        "detail_description": "This is a first-in-human Phase 1b/2, multi-center, open-label, dose-escalation and expansion\r\n      study to:\r\n\r\n        -  Evaluate the safety profile and MTD of RP-3500 when administered orally in combination\r\n           with Niraparib or Olaparib to establish the recommended Phase 2 dose and schedule.\r\n\r\n        -  Characterize the PK profile of RP-3500 in combination with Niraparib or Olaparib\r\n\r\n        -  Assess anti-tumor activity associated with RP-3500 in combination with Niraparib or\r\n           Olaparib\r\n\r\n        -  Examine biomarker responses and establish a correlation with RP-3500 treatment in\r\n           combination with Niraparib or Olaparib.\r\n\r\n      After the RP2D and schedule is determined, expansion cohort(s) for RP-3500 in combination\r\n      with Niraparib or Olaparib will be enrolled to study the anti-tumor effect, and further\r\n      examine the safety, PK, and pharmacodynamic (PD).",
        "official_title": "Phase 1b/2 Study of ATR InhibiTor RP-3500 and PARP Inhibitor Combinations in Patients With Molecularly Selected Cancers (ATTACC)",
        "_phase_sort_order": 3,
        "collaborators": [],
        "associated_studies": [],
        "outcome_measures": [
            {
                "timeframe": "Up to 30 days after last administration of study intervention",
                "name": "Phase Ib - Safety and Tolerability Tolerability of niraparib or olaparib in combination with RP-3500 by assessing the grade and frequency of adverse events and serious adverse events.",
                "description": "To determine the safety and tolerability of niraparib or olaparib in combination with RP-3500 in patients with advanced solid tumors by assessing the grade and frequency of adverse events and serious adverse events",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "At the end of cycle 1 (each cycle is 21 days)",
                "name": "Primary Phase 1b - Define Maximum Tolerated Dose (MTD) of RP-3500-03 in combination with niraparib or olaparib and Recommended Phase 2 dose (RP2D) and preferred schedule by assessing the frequency of Dose limiting Toxicities observed at each dose level",
                "description": "To define the MTD of RP-3500-03 in combination with niraparib or olaparib and determine a recommended Phase 2 dose (RP2D) and preferred schedule by assessing the frequency of Dose limiting Toxicities (DLTs) observed at each dose level",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "While on study therapy, every 6 weeks for first 5 months and then every 9 weeks thereafter",
                "name": "Primary Phase 2 - Assess preliminary anti-tumor activity of RP-3500 with niraparib or olaparib in patients with eligible advanced solid tumors by CT/MRI Response evaluation criteria (RECIST 1.1)",
                "description": "To preliminarily assess the antitumor activity of RP-3500 with niraparib or olaparib in patients with eligible advanced solid tumors by CT/MRI Response evaluation criteria (RECIST 1.1)",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Through Cycle 1 and 2 (each cycle is 21 days)",
                "name": "To assess plasma concentrations of RP-3500 and niraparib or olaparib with calculations of area under the plasma concentration-time curve 0-6 hours post dose (AUC0-6).",
                "description": "To assess plasma concentrations of RP-3500 and niraparib or olaparib with calculations of area under the plasma concentration-time curve 0-6 hours post dose (AUC0-6).",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Through Cycle 1 and 2 (each cycle is 21 days)",
                "name": "To assess plasma concentrations of RP-3500 and niraparib or olaparib with calculations of maximum observed plasma concentration (Cmax).",
                "description": "To assess PK parameters of RP-3500 in combination with niraparib or olaparib",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Through Cycle 1 and 2 (each cycle is 21 days)",
                "name": "To assess plasma concentrations of RP-3500 and niraparib or olaparib with calculations of time to maximum observed plasma concentration (Tmax)",
                "description": "To assess plasma concentrations of RP-3500 and niraparib or olaparib with calculations of time to maximum observed plasma concentration (Tmax)",
                "type_code": "SECONDARY"
            }
        ],
        "phase": "I_II",
        "central_contact": {
            "phone": null,
            "name": null,
            "type": null,
            "email": null
        },
        "primary_purpose": "TREATMENT",
        "number_of_arms": 2,
        "_study_protocol_type_sort_order": 0,
        "nct_id": "NCT04972110",
        "biomarkers": [],
        "classification_code": null,
        "current_trial_status_date": "2021-07-21",
        "diseases": [
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": true,
                "synonyms": [
                    "Advanced Malignant Solid Neoplasm",
                    "Advanced Non-Hematologic Malignancy",
                    "Advanced Solid Neoplasm",
                    "Advanced Solid Tumor"
                ],
                "nci_thesaurus_concept_id": "C129707",
                "name": "Advanced Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C127155",
                    "C9270"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Solid Tumour",
                    "Solid tumor, NOS",
                    "Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C9292",
                "name": "Solid Tumor",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm, malignant",
                    "Cancer",
                    "Malignant Growth",
                    "Tumor, malignant, NOS",
                    "Malignant Tumor",
                    "Malignancy",
                    "CA",
                    "Unclassified tumor, malignant",
                    "Malignant Neoplastic Disease"
                ],
                "nci_thesaurus_concept_id": "C9305",
                "name": "Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Metastatic Cancer"
                ],
                "nci_thesaurus_concept_id": "C36263",
                "name": "Metastatic Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C4968",
                    "C3261"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Secondary Malignancy",
                    "Secondary Cancer"
                ],
                "nci_thesaurus_concept_id": "C4968",
                "name": "Secondary Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9305",
                    "C36255"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C7062",
                "name": "Neoplasm by Special Category",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3262"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm, secondary",
                    "Secondary Tumor",
                    "Tumor, secondary"
                ],
                "nci_thesaurus_concept_id": "C36255",
                "name": "Secondary Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "disease term",
                    "Disease",
                    "Diseases and Disorders",
                    "disease type",
                    "Disease or Disorder",
                    "Diagnosis",
                    "disease_term",
                    "condition",
                    "disease_type",
                    "Diseases",
                    "Disease or Disorder, Non-Neoplastic",
                    "Disorders",
                    "Disorder"
                ],
                "nci_thesaurus_concept_id": "C2991",
                "name": "Other Disease",
                "type": [
                    "maintype"
                ],
                "parents": []
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Advanced Cancer"
                ],
                "nci_thesaurus_concept_id": "C9270",
                "name": "Advanced Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36263"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Malignant Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C132146",
                "name": "Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9292",
                    "C9305"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Metastatic Solid Neoplasm",
                    "Metastatic Solid Tumor",
                    "Metastatic Tumor",
                    "Metastatic Malignant Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C127155",
                "name": "Metastatic Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36263",
                    "C132146"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Metastatic Tumor",
                    "Tumor, metastatic",
                    "Neoplasm, metastatic"
                ],
                "nci_thesaurus_concept_id": "C3261",
                "name": "Metastatic Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasms, NOS",
                    "Neoplasia",
                    "Tumor, NOS",
                    "Neoplastic Growth",
                    "Neoplasm",
                    "Neoplastic Disease",
                    "tumor",
                    "Neoplasm, NOS"
                ],
                "nci_thesaurus_concept_id": "C3262",
                "name": "Other Neoplasm",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C2991"
                ]
            }
        ],
        "_primary_purpose_sort_order": 0,
        "protocol_id": "RP-3500-03",
        "active_sites_count": 5,
        "lead_org_cancer_center": null,
        "arms": [
            {
                "interventions": [
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Molecularly Targeted Therapy Agent",
                            "Anti-tumor Targeted Therapy Agent",
                            "Targeted Therapeutic Agent",
                            "Targeted Agent"
                        ],
                        "nci_thesaurus_concept_id": "C163758",
                        "name": "Targeted Therapy Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C274"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C2189",
                        "name": "Signal Transduction Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C274"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "ATR Kinase Inhibitor"
                        ],
                        "nci_thesaurus_concept_id": "C155926",
                        "name": "ATR Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C61074"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C80059",
                        "name": "Niraparib",
                        "description": "An inhibitor of poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity. PARP Inhibitor MK4827 inhibits PARP activity, enhancing the accumulation of DNA strand breaks and promoting genomic instability and apoptosis. The PARP family of proteins detect and repair single strand DNA breaks by the base-excision repair (BER) pathway. The specific PARP family member target for PARP inhibitor MK4827 is unknown. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional",
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C62554"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [
                            "Lynparza"
                        ],
                        "nci_thesaurus_concept_id": "C71721",
                        "name": "Olaparib",
                        "description": "A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional",
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C62554"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1908",
                        "name": "Drug, Food, Chemical or Biomedical Material",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": []
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Antineoplastic Drugs",
                            "Cancer Drug",
                            "Anti-Tumor Agents",
                            "Antiproliferative Agents",
                            "Chemotherapeutic Agents, Neoplastic Disease",
                            "Tumor-Specific Treatment Agents",
                            "Anti-Cancer Agents",
                            "Anti-Tumor Drugs",
                            "Antineoplastics",
                            "Antiproliferative Drugs"
                        ],
                        "nci_thesaurus_concept_id": "C274",
                        "name": "Antineoplastic Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Antineoplastic Protein Antagonist",
                            "Anti-cancer Protein Inhibitor"
                        ],
                        "nci_thesaurus_concept_id": "C129824",
                        "name": "Antineoplastic Protein Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C2189"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Pharmaceutical Agent",
                            "Agent",
                            "Pharmacological Substance",
                            "Drug",
                            "Pharmaceuticals",
                            "Pharmacologic Agent",
                            "Drug Substance"
                        ],
                        "nci_thesaurus_concept_id": "C1909",
                        "name": "Pharmacologic Substance",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1908"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C174206",
                        "name": "ATR Inhibitor RP-3500",
                        "description": null,
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C129825",
                            "C155926"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Poly (ADP-Ribose) Polymerase Inhibitor",
                            "Poly(ADP-Ribose) Polymerase Inhibitor"
                        ],
                        "nci_thesaurus_concept_id": "C62554",
                        "name": "PARP Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C471",
                            "C163758"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1404",
                        "name": "Protein Kinase Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C471"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-cancer Enzyme Inhibitor"
                        ],
                        "nci_thesaurus_concept_id": "C129825",
                        "name": "Antineoplastic Enzyme Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C129824",
                            "C471"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C61074",
                        "name": "Serine/Threonine Kinase Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1404"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Enzyme Inhibitor Agent",
                            "Enzyme Inhibitor Drug",
                            "Enzyme Antagonist"
                        ],
                        "nci_thesaurus_concept_id": "C471",
                        "name": "Enzyme Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    }
                ],
                "name": "Arm not specified",
                "description": null,
                "type": null
            },
            {
                "interventions": [],
                "name": "Phase 2 Expansion Cohorts",
                "description": "Expansion cohort with RP-3500 + Niraparib and/or Expansion cohort RP-3500 + Olaparib",
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "Phase Ib Dose Escalation",
                "description": "Multiple dose levels of RP-3500 for oral administration in combination with Niraparib and/or Multiple dose levels of RP-3500 for oral administration in combination with Olaparib",
                "type": "EXPERIMENTAL"
            }
        ],
        "study_model_code": null,
        "nci_id": "NCI-2021-08395",
        "why_study_stopped": null,
        "brief_summary": "The primary purpose of this study is to assess the safety and tolerability of Niraparib or\r\n      Olaparib in combination with RP-3500, in patients with eligible advanced solid tumors,\r\n      determine the maximum tolerated dose (MTD) of RP-3500 in combination with Niraparib or\r\n      Olaparib, examine pharmacokinetics (PK) and assess anti-tumor activity.",
        "brief_title": "Study of RP-3500 With Niraparib or Olaparib in Advanced Solid Tumors",
        "status_history": [
            {
                "status_date": "2021-07-21T00:00:00.000001",
                "status": "ACTIVE"
            },
            {
                "status_date": "2021-07-16T00:00:00",
                "status": "IN_REVIEW"
            }
        ],
        "study_population_description": null,
        "sampling_method_code": null,
        "minimum_target_accrual_number": 108,
        "_current_trial_status_sort_order": 0,
        "start_date": "2021-07-21",
        "record_verification_date": "2022-01-01",
        "ctep_id": null,
        "current_trial_status": "Active",
        "study_model_other_text": null,
        "masking": {
            "role_caregiver": null,
            "masking": null,
            "role_investigator": null,
            "role_outcome_assessor": null,
            "role_subject": null,
            "allocation_code": "Non-Randomized Trial"
        },
        "acronym": "ATTACC",
        "nci_funded": "Indirect",
        "anatomic_sites": [
            "Multiple"
        ],
        "ccr_id": null,
        "start_date_type_code": "ACTUAL",
        "principal_investigator": null,
        "study_source": "Industrial",
        "completion_date": "2023-11-01",
        "study_subtype_code": null,
        "study_protocol_type": "Interventional"
    }
]